Recruiting
Phase 1

Study of REM-422 in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

Sponsor:

Remix Therapeutics

Code:

NCT06118086

Conditions

Adenoid Cystic Carcinoma

Metastatic Adenoid Cystic Carcinoma

Recurrent Adenoid Cystic Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REM-422

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information